



CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

November 15, 2004
Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

George J. Brewer, Sofia D. Merajver
and Dimitri Coucouvanis

Serial No.: 10/796,782

Filing Date: March 09, 2004

For: Methods and Compositions for the
Treatment of Angiogenic Diseases
(As Amended)

Group Art Unit: 1616

Examiner: Unknown

Atty. Dkt. No.: 4100.001099

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. As the filing date of the present application is after June 30, 2003, copies of U.S. patents are no longer required by 37 C.F.R. § 1.98(a)(2) and copies of the listed U.S. patents are not included herewith.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees are due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Office should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4100.001099.

Respectfully submitted
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079

Date: November 15, 2004

Form PTO-1449 (modified)

Atty. Docket No.
4100.001099Serial No.
10/796,782

List of Patents and Publications for Applicant's

Applicant
Brewer *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
March 09, 2004Group:
1616U.S. Patent Documents
See Page 1-2Foreign Patent Documents
See Page 2Other Art
See Page 2-7

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A16	5,112,598	05/12/92	Biesalski	424		
	A17	5,527,533	06/18/96	Tso <i>et al.</i>	424		
	A18	5,556,611	09/17/96	Biesalski	424		
	A19	5,583,153	12/10/96	Brahn	514		
	A20	5,970,974	10/26/99	Van der Linden <i>et al.</i>	128		
	A21	5,954,047	09/21/99	Armer <i>et al.</i>	128		
	A22	5,950,619	09/14/99	van der Linden <i>et al.</i>	128		
	A23	5,698,155	12/16/97	Grosswald <i>et al.</i>	264		
	A24	5,639,725	06/17/97	O'Reilly <i>et al.</i>	514		
	A25	4,765,539	08/23/88	Noakes <i>et al.</i>	239		
	A26	3,916,899	11/04/75	Theeuwes <i>et al.</i>	128		
	A27	3,845,770	11/05/74	Theeuwes <i>et al.</i>	128		
	A28	4,604,278	08/05/86	Reilly <i>et al.</i>	423		
	A29	4,343,746	08/10/82	Anglin <i>et al.</i>	556		
	A30	2,909,541	10/20/59	Hugel	260		
	A31	6,703,050	03/09/04	Brewer <i>et al.</i>	424		
	A32	5,639,757	June 17, 1997	Dow <i>et al.</i>	514	261	
	A33	5,712,291	Jan. 27, 1998	D'Amato	514	323	
	A34	5,753,230	May 19, 1998	Brooks <i>et al.</i>	424	158.1	
	A35	5,972,922	Oct. 26, 1999	Wilks <i>et al.</i>	514	178	

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A36	2004/0009237 A1	Jan. 15, 2004	Brewer	424	617	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 1 107 795 B1	Nov. 27, 2002	EP			
	B2	EP 1 234 585 A2	Aug. 28, 2002	EP			
	B3	WO 00/13712	Mar. 16, 2000	PCT			
	B4	WO 2004/009072	Jan. 29, 2004	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C83	Benjamin <i>et al.</i> , "Selective Ablation of Immature Blood Vessels in Established Human Tumors Follows Vascular Endothelial Growth Factor Withdrawal," <i>J. Clin. Invest.</i> , 103(2):159-165, 1999.
	C84	Borgstrom <i>et al.</i> , "Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors <i>In Vivo</i> ," <i>The Prostate</i> , 35:1-10, 1998.
	C85	Jeannin <i>et al.</i> , "Molecular Architecture of Copper(1) Thiometallate Complexes. Examples of a Cubane with an Extra Face, (NPr ₄) ₃ [MS ₄ Cu ₄ Cl ₅]," <i>Inorganic. Chimica. Acta.</i> , 198-200:493-500, 1992.
	C86	Malavé <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngenic Mice," <i>J. Natl. Cancer Inst.</i> , 62(1):83-88, 1979.
	C87	Passaniti <i>et al.</i> , "Methods in Laboratory Investigation," <i>Laboratory Investigation</i> , 67(4):519-528, 1992.
	C88	Sécheresse <i>et al.</i> , "Heterobimetallic Aggregates of Copper(1) with Thio-tungstate and -molybdate. Cation Effect in Aggregation of Ms ₄ Cu ₄ Cl ₅ Units, a Crystallographic Study," <i>J. Chem. Soc. Dalton Trans.</i> , 11:2875-2881, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C89	Sugiura <i>et al.</i> , "Studies in a Tumor Spectrum," <i>Cancer Research</i> , 15:38-51, 1955.
	C90	Takai <i>et al.</i> , "Preparation, Structure and Properties of Mixed-Metal Trinuclear Complex: (Pr ₄ N) ₂ [MoO(WS ₄) ₂]," <i>Chemistry Letters</i> , 8:645-646, 1996.
	C91	Bajou <i>et al.</i> , "Absence of Host Plasminogen Activator Inhibitor I Prevents Cancer Invasion and Vascularization," <i>Nat. Med.</i> , 4:923-928, 1998.
	C92	Bamba <i>et al.</i> , "Release Mechanisms in Gel Forming Sustained Release Preparations," <i>Int. J. Pharm.</i> , 2:307, 1979.
	C93	Blood <i>et al.</i> , "Tumor Interactions With the Vasculature: Angiogenesis and Tumor Metastasis," <i>Biochim. Biophys. Acta.</i> , 1032:89-118, 1990.
	C94	Brown, "Metal Toxicity and Therapeutic Intervention," <i>Biochem. Soc. Trans.</i> , 30:742- 745 2002.
	C95	Brown, "Copper and Prion Disease," <i>Brain Res. Bull.</i> , 55:165-173, 2001.
	C96	Carri <i>et al.</i> , "Copper-Dependent Oxidative Stress, Alteration of Signal Transduction and Neurodegeneration in Amyotrophic Lateral Sclerosis," <i>Funct. Neurol.</i> , 16:181-188, 2001.
	C97	Chakravarty <i>et al.</i> , "Serum Copper in Malignant Neoplasia with Special Reference to the Cervix Uteri," <i>J. Cancer Res. Clin. Oncol.</i> , 108: 312-315, 1984.
	C98	Chambers <i>et al.</i> , "Macrophage Colony-Stimulating Factor Mediates Invasion of Ovarian Cancer Cells Through Urokinase," <i>Cancer Research</i> , 55:1578-1585, 1995.
	C99	Chen <i>et al.</i> , "TNF-RI Signaling: A Beautiful Pathway," <i>Science</i> , 296:1634-1635, 2002.
	C100	Crowley <i>et al.</i> , "Prevention of Metastasis by Inhibition of the Urokinase Receptor," <i>Proc. Nat'l. Acad. Sci. USA</i> , 90:5021-5025, 1993.
	C101	During <i>et al.</i> , "Controlled Release of Dopamine from a Polymeric Brain Implant; In vivo Characterization," <i>Ann. Neurol.</i> , 25:351-356, 1989.
	C102	Folkman, "Anti-Angiogenesis: New Concept for Therapy of Solid Tumors," <i>Ann. Surg.</i> , 175: 409-416, 1972.
	C103	Folkman, "Angiogenesis Inhibitors Generated by Tumors," <i>Mol. Med.</i> , 1(2):120-122 1995.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C104	Gnjec <i>et al.</i> , "Transition Metal Chelator Therapy - A potential Treatment For Alzheimer's Disease?" <i>Front Biosci.</i> , 16-23, 2002.
	C105	Goodson, "Medical Applications of Controlled Release" 2:115-138, 1984.
	C106	Gorelik <i>et al.</i> , "Control of Lung Metastasis Progression in Mice: Role of Growth Kinetics of 3LL Lewis Lung Carcinoma and Host Immune Reactivity," <i>J. Nat'l. Cancer Inst.</i> , 65: 1257-1264, 1980.
	C107	Gorelik, <i>et al.</i> , "Host's Immune State and Kinetics of Local Tumor Growth Control-Progression of Postoperative Lung Metastasis," <i>Rec. Results Cancer Res.</i> , 75:20-28, 1980.
	C108	Hanada <i>et al.</i> , "Regulation of Cytokine Signaling and Inflammation," <i>Cytokine Growth Factor Rev.</i> , 13: 413-421, 2002.
	C109	Hanahan <i>et al.</i> , "Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis," <i>Cell</i> , 86(3):355-364, 1996.
	C110	Hilgard <i>et al.</i> , "Oral Anticoagulation in the Treatment of a Spontaneously Metastasising Murine Tumour (3LL)," <i>Br. J. Cancer</i> , 35:78-86, 1977.
	C111	Howard <i>et al.</i> , "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," <i>J. Neurosurg.</i> , 71:105-112, 1989.
	C112	Isakov <i>et al.</i> , "An Immune Response Against the Alloantigens of the 3LL Lewis Lung Carcinoma Prevents the Growth of Lung Metastases, but Not of Local Allografts," <i>Invasion Metas.</i> , 2:12-32, 1982.
	C113	Kleinman <i>et al.</i> , "Basement Membrane Complexes with Biological Activity," <i>Biochem.</i> , 25: 312-318, 1986.
	C114	Koch <i>et al.</i> , "Interleukin-8 as a Macrophage-Derived Mediator of Angiogenesis," <i>Science</i> , 258:1798-1801, 1992.
	C115	Kowalik-Jankowska <i>et al.</i> , "Possible Involvement of Copper (II) in Alzheimer Disease," <i>Environ. Health Perspect.</i> , 5:869-870, 2002.
	C116	Langer <i>et al.</i> , "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," <i>J. Macromol. Sci. Rev. Macromol. Chem.</i> , 23:61-126, 1983.
	C117	Langer, "New Methods of Drug Delivery," <i>Science</i> , 249:1527-1533, 1990.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C118	Levy <i>et al.</i> , Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> , 228:190-192, 1985.
	C119	Llanos <i>et al.</i> , "The Molecular Basis of Copper Homeostasis and Copper-Related Disorders," <i>DNA Cell Biol.</i> , 21:259-270, 2002.
	C120	Loskutoff <i>et al.</i> , "A Powerful Genetic Model to Study Hemostatic Gene Expression in Obesity/NIDDM," <i>Ann. N.Y. Acad. Sci.</i> , 902:272-282, 2000.
	C121	Malave <i>et al.</i> , "Influence of Inoculation Site on Development of the Lewis Lung Carcinoma and Suppressor Cell Activity in Syngeneic Mice," <i>J. Nat'l. Cancer Inst.</i> , 62:83-88, 1979.
	C122	Mandinov <i>et al.</i> , "Copper Chelation Represses the Vascular Response To Injury" <i>PNAS</i> , 100:6700-6705, 2003.
	C123	Maynard <i>et al.</i> , "Overexpression of Alzheimer's Disease Amyloid- β Opposes the Age-Dependent Elevations of Brain Copper and Iron," <i>J. Biol. Chem.</i> , 277(47):44670-44676, 2002.
	C124	Millauer <i>et al.</i> , "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types <i>In vivo</i> ," <i>Cancer Res.</i> 56:1615-1620, 1996.
	C125	Min <i>et al.</i> , "Urokinase Receptor Antagonists Inhibit Angiogenesis and Primary Tumor Growth in Syngeneic Mice," <i>Cancer Res.</i> , 56:2428-2433, 1996.
	C126	Miyake <i>et al.</i> , "Transforming Growth Factor- β 1 Stimulates Contraction of Human Glioblastoma Cell-Mediated Collagen Lattice Through Enhanced α 2 Integrin Expression," <i>J. Neuropathol. Exp. Neurol.</i> , 59:18-28, 2000.
	C127	Nguyen <i>et al.</i> , "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane," <i>Microvascular Res.</i> , 47:31-40, 1994.
	C128	Odedra <i>et al.</i> , "Low Molecular Weight Angiogenesis Factors," <i>Pharmac. Ther.</i> , 49:111-124, 1991.
	C129	Osawa <i>et al.</i> , "Tumor Necrosis Factor Alpha-Induced Interleukin-8 Production via NF-kB and Phosphatidylinositol 3-Kinase/Akt Pathways Inhibits Cell Apoptosis in Human Hepatocytes," <i>Infect. Immun.</i> , 70:6294-6301, 2002.
	C130	Pan <i>et al.</i> , "Copper Deficiency Induced by Tetrathiomolybdate Suppresses Tumor Growth and Angiogenesis," <i>Cancer Res.</i> , 62: 4854-4859, 2002.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C131	Parish <i>et al.</i> , "A Basement-Membrane Permeability Assay Which Correlates with the Metastatic Potential of Tumor Cells," <i>Int. J. Cancer</i> , 52:378-383, 1992.
	C132	Parke <i>et al.</i> , "Characterization and Quantification of Copper Sulfate-Induced Vascularization of the Rabbit Cornea" <i>Am. J. Pathol.</i> , 130:173-178, 1988.
	C133	Passaniti <i>et al.</i> , "A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Lab. Invest.</i> , 67:519-528, 1992.
	C134	Patstone <i>et al.</i> , "Copper and Calcium Binding Motifs in the Extracellular Domains of Fibroblast Growth Factor Receptors," <i>J. Biol. Chem.</i> , 271(7):3343-3346, 1996.
	C135	Perry <i>et al.</i> , "The Role of Iron and Copper in the Aetiology of Neurodegenerative Disorders," <i>CNS Drugs</i> , 16:339-352, 2002.
	C136	Rabbani <i>et al.</i> , "Prevention of Prostate-Cancer Metastasis <i>In Vivo</i> By a Novel Synthetic Inhibitor of Urokinase-Type Plasminogen Activator (uPA)," <i>Int. J. Cancer</i> , 63:840-845, 1995.
	C137	Redman <i>et al.</i> , "Phase II Trial of Tetrathiomolybdate in Patients with Advanced Kidney Cancer," <i>Clin. Cancer Res.</i> , 9:1666-1672, 1996.
	C138	Rupnick <i>et al.</i> , "Adipose Tissue Mass Can Be Regulated Through the Vasculature," <i>Proc. Natl. Acad. Sci.</i> , 99:10730-10735, 2002.
	C139	Saudek <i>et al.</i> , "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," <i>N. Engl. J. Med.</i> , 321:574, 1989.
	C140	Schnaper <i>et al.</i> , "Plasminogen Activators Augment Endothelial Cell Organization In Vitro by Two Distinct Pathways," <i>J. Cell. Physiol.</i> , 165:107-118, 1995.
	C141	Sefton, "Implantable Pumps," <i>CRC Crit. Rev. Biomed. Eng.</i> , 14(3):201-240, 1987.
	C142	Sen <i>et al.</i> , "Copper-Induced Vascular Endothelial Growth Factor Expression and Wound Healing," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 282:H1821-H1827, 2002.
	C143	Shockley <i>et al.</i> , "Penetration of Tumor Tissue by Antibodies and Other Immunoproteins," <i>Ann. N.Y. Acad. Sci.</i> , 617:367-382, 1991.
	C144	Strausak <i>et al.</i> , "Copper in Disorders with Neurological Symptoms: Alzheimer's, Menkes, and Wilson Diseases," <i>Brain Res. Bull.</i> , 55:175-185, 2001.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. 4100.001099	Serial No. 10/796,782
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Brewer <i>et al.</i>	
		Filing Date: March 09, 2004	Group: 1616
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Page 2-7</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C145	Talmadge <i>et al.</i> , "Enhanced Metastatic Potential of Tumor Cells Harvested From Spontaneous Metastases of Heterogeneous Murine Tumors," <i>J. Nat'l. Cancer Inst.</i> , 69:975-980, 1982
	C146	Thakur <i>et al.</i> , "Indium-111-Labeled Leukocytes for the Localization of Abscesses: Preparation, Analysis, Tissue Distribution, and Comparison with Gallium-67 Citrate in Dogs," <i>J. Lab. Clin. Med.</i> , 89:217-228, 1977.
	C147	Treat <i>et al.</i> , in "Liposomes in the Therapy of Infectious Disease and Cancer," Lopez-Berestein and Fidler (eds.), Liss, New York, 353-365, 1989.
	C148	Van Golen <i>et al.</i> , "Suppression of Tumor Recurrence and Metastasis by a Combination of the PHSCN Sequence and the Antiangiogenic Compound Tetrathiomolybdate in Prostate Carcinoma," <i>Neoplasia</i> , 4(5):373-379, 2002.
	C149	Verma <i>et al.</i> , "Osmotically Controlled Oral Drug Delivery," <i>Drug Develop. Indus. Pharm.</i> , 26(7):665-708, 2000.
	C150	Verschoye <i>et al.</i> , "Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation," <i>British J. Cancer</i> , 80, Suppl. 2, 96, 1999.
	C151	Volpert <i>et al.</i> , "Captopril Inhibits Angiogenesis and Slows the Growth of Experimental Tumors in Rats," <i>J. Clin. Invest.</i> , 98:671-679, 1996.
	C152	Xing <i>et al.</i> , "Overexpression of Urokinase Receptor in Breast Cancer Cells Results in Increased Tumor Invasion, Growth and Metastasis," <i>Int. J. Cancer</i> , 67:423-429, 1996.
	C153	International Search Report for PCT/US03/003210, mailed December 18, 2003 (4100.003210).
	C154	International Search Report for PCT/US03/23031, mailed June 29, 2004

EXAMINER:	DATE CONSIDERED:
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	